RxDoctor Payments Data

Colleen Folkers

Adult Health · Chicago, ILNPI 1043597131

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $84,033 of the $85,769 with a category attached, or 98.0%. Gilead accounts for 98.8% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $22,041, 2.2 times the $9,910 reported in 2021. Among adult health clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$85,769in general payments, 2019–2025

Across 32 payments — averaging $2680.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$85K
  • AbbVie$465
  • Novo Nordisk$207
  • Madrigal Pharmaceuticals$176
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$74
  • Ipsen Biopharmaceuticals, Inc$68

What the payments were for

  • Consulting fees$84,03398%
  • Food & beverage$1,7362%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$85,769 in reported general payments places this provider in the 95th percentile of 553 adult health providers in Illinois.

See all adult health providers in Illinois

Medicare billing

Part B allowed, 2024
$18,985
Medicare patients
129
Services billed
217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide28$39,816
Ursodiol46$6,060
Tacrolimus12$1,241
Lactulose18$800
Azathioprine11$262
Spironolactone31$255
Furosemide32$92

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$84,779$39,81628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 553 adult health providers in Illinois.

Other adult health in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →